Related Experiment Video
Updated: Apr 20, 2026
Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad
Published on: January 20, 2019
Animal models for exploring the pharmacokinetics of breast cancer therapies
Omar M Rashid1, Kazuaki Takabe
1H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL , USA.
Introduction:
Despite massive expenditures in research and development to cure breast cancer, few agents that pass preclinical trials demonstrate efficacy in humans. Although this endeavor relies on murine models to screen for efficacy before progressing to clinical trials, historically there has been little focus on the validation of these models, even in the era of targeted therapy where understanding the genetic signatures of tumors under study is critical.
Areas Covered:
This review includes the transgenic, xenograft, and syngeneic murine breast cancer models, the ectopic, orthotopic and intravenous methods of cell implantation, and the ethics of animal experimentation. It also includes the latest data on tumor gene expression and the issues to consider when exploring the pharmacokinetics and efficacy of breast cancer therapies.
Expert Opinion:
Breast cancer drug development is expensive and inefficient without a consensus preclinical murine model. Investigators must approach the choice of murine model with the same sophistication that is applied to the choice of in vitro assays to improve efficiency. Understanding the limitations of each model available, including the nuances of tumor gene signatures, is critical for investigators exploring the phamacokinetics and efficacy of breast cancer therapies, especially in the context of gene profiling and individualized targeted therapy.
Insights
Selecting appropriate preclinical murine models is crucial for efficient breast cancer drug development. Understanding model limitations, including tumor gene signatures, enhances therapeutic efficacy and targeted therapy success.
Area of Science:
- Oncology
- Translational Medicine
- Pharmacology
Background:
- Breast cancer research faces challenges with preclinical models failing to predict human efficacy.
- Limited validation of murine models hinders the development of targeted therapies, despite critical importance of tumor genetic signatures.
Purpose of the Study:
- To review current murine models for breast cancer research.
- To highlight critical factors for selecting appropriate models in drug development.
Main Methods:
- Review of transgenic, xenograft, and syngeneic murine breast cancer models.
- Analysis of cell implantation methods (ectopic, orthotopic, intravenous) and animal experimentation ethics.
- Inclusion of tumor gene expression data and pharmacokinetic/efficacy considerations.
Main Results:
- Lack of a consensus preclinical murine model leads to expensive and inefficient breast cancer drug development.
- Sophisticated selection of murine models, akin to in vitro assays, is necessary for improved efficiency.
Conclusions:
- Understanding murine model limitations, including tumor gene signatures, is vital for optimizing breast cancer therapy research.
- Informed model selection is critical for advancing pharmacokinetics and efficacy studies, especially for gene profiling and personalized medicine.
